StreetAlpha.app
Home › Stocks › CDXS

Codexis, Inc. (CDXS)

$1.07
▲ +2.39%
LAST CLOSE · NOV 17

Codexis makes engineered enzymes and manufacturing services that help pharmaceutical companies produce drug therapeutics. It last closed at $1.07 on Nov 17, up 2.39% on the day. CDXS last reported earnings on Tue, Aug 11, 2026.

AI Auto Pilots
Is CDXS in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$88.3M
+66.9% vs a year ago
Net income
−$19.2M
−21.8% margin
EPS (diluted)
−$0.18
Free cash flow
−$12.1M
−13.7% margin
Valuation
Market cap
$117.3M
109.6M shares
P/E
–
No P/E while losing money
Price to sales
1.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$29.2M
At Sep 30
Debt
$41.3M
At Sep 30
Shareholder equity
$51.2M
Shares outstanding
109.6M
At Nov 9
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $104.8M$104.8MFY2021FY2022: $138.6M$138.6MFY2022FY2023: $70.1M$70.1MFY2023FY2024: $59.3M$59.3MFY2024FY2025: $70.4M$70.4MFY2025

From CDXS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Aug 11
2026 · After the close (AMC)
Reported EPS
-$0.13
vs -$0.17 est. · beat
Year-ago EPS
—
Not on file
Options-implied move
±27.6%
Priced in before that report
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated CDXS in the past 90 days, not enough for a consensus
Average 12-month target
$5.00
▲ 367.3% upside

Based on 1 analyst who set a price target on CDXS in the past 90 days. The average target is $5.00, with a high of $5.00 and a low of $5.00, compared with the last close of $1.07.

Low $5.00Avg $5.00High $5.00
Blue marker: last close $1.07
Highest target$5.00
Average target$5.00
Lowest target$5.00
Latest rating changes
Stephens & Co.Reiterated
Nov 16Buy$5
Piper SandlerMaintained
Aug 17Buy$8
DateFirmActionRatingPrice target
Nov 16Stephens & Co.ReiteratedBuy$5
Aug 17Piper SandlerMaintainedBuy$8
Loading…

Technical Analysis

CDXS · as of the Nov 17 close · updated after every close
Downtrend

The stock is 6% below its 20 day and 19% below its 50 day average. It is 67% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 44). The nearest support is the Pivot S1 at $1.04, and the nearest resistance the Pivot at $1.08.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 9.1%/day
Key levels
$2.9852 week high+178.5%
$1.79200 day average+67.3%
$1.55100 day average+44.9%
$1.2750 day average+18.7%
$1.17Swing high (Nov 9)+9.3%
$1.1420 day average+6.5%
$1.11Pivot R1+3.7%
$1.08Pivot+0.9%
$1.07Last close
$1.04Pivot S1−2.8%
$0.99Swing low (Nov 5)−7.5%
$0.9052 week low−15.9%
Indicators
RSI (14)43.64Middle of its rangeNeutral
MACD-0.08Below its signal lineBearish
Stochastic44.0Middle of its rangeNeutral
ADX (14)36.4Trending down
Williams %R-57.5Oversold below −80, overbought above −20Neutral
CCI (20)-45.1Oversold below −100, overbought above 100Neutral
Rate of change−0.9%Change over 10 sessionsBearish
ATR (14)$0.10Typical daily range, 9.1% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CDXS

What happened before

See how CDXS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow CDXS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How CDXS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2010.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in CDXS in the last 90 days.

Loading…

See today’s whale options flow across the market →

CDXS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●73 buying vs 68 selling
  • ▲Held by funds +4.7 pts
  • ▼Funds holding -20
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding130150−13.3%
In funds' top 1000–
Held by funds68.6%63.9%+4.7 pts
New / increased16 / 5728 / 63−19.8%
Reduced / sold out33 / 3535 / 12+44.7%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CDXS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CDXS is in one of them and how their past CDXS trades turned out.

CDXS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CDXS in an article yet. Here's the latest on the wider market.

CDXS Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed May 8
Who traded CDXS · since 2018
Latest 1 filing
$1K – $15KTraded Apr 6, 2018Filed May 8, 2018
PersonTypeAmountTradedFiledDelay
Lamar SmithR · TXBuy$1K – $15KApr 6, 2018May 8, 201832 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Codexis

Codexis develops engineered enzymes and other proteins that improve how drugs are made, using its CodeEvolver platform. Its ECO Synthesis platform uses enzymes to manufacture RNA interference therapeutics, and it offers method development, process development and manufacturing support to drug developers. Its small molecule business sells optimized enzymes to large pharmaceutical companies to raise yields and purity. The company is based in Redwood City, California.

Headquarters
Redwood City, CA
Founded
2002